Nkarta, Inc. – Trademark Portfolio
Entity Type: 03
Nkarta, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 3 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include NKARTA. The owner is based in San Francisco, CA.
1700 Owens Street, Suite 530
San Francisco, CA 94158
Showing of trademarks Trademarks
Trademark Classifications
Nkarta, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Nkarta, Inc. have?
Nkarta, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending, 1 abandoned.
What trademark classes does Nkarta, Inc. file in?
Nkarta, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 44 (Medical Services), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.
What are Nkarta, Inc.'s most well-known trademarks?
Nkarta, Inc.'s registered trademark portfolio includes well-known marks such as NKARTA. These are among 1 currently registered trademark in the portfolio.
What is Nkarta, Inc.'s trademark registration success rate?
Nkarta, Inc. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 2 applications are pending review.